Page 18 - 《中国药房》2025年16期

255-258. （4）：530-537.
[ 9 ] KOTHEKAR A T，DIVATIA J V，MYATRA S N，et al. [22] FOURNIER A，EGGIMANN P，PAGANI J L，et al. Im‐
Clinical pharmacokinetics of 3-h extended infusion of me‐ pact of the introduction of real-time therapeutic drug
ropenem in adult patients with severe sepsis and septic monitoring on empirical doses of carbapenems in criti‐
shock：implications for empirical therapy against Gram- cally ill burn patients[J]. Burns，2015，41（5）：956-968.
negative bacteria[J]. Ann Intensive Care，2020，10（1）：4. [23] MACHADO A S，OLIVEIRA M S，SANCHES C，et al.
[10] FURTADO G H，CARDINAL L，MACEDO R S，et al. Clinical outcome and antimicrobial therapeutic drug moni‐
Pharmacokinetic/pharmacodynamic target attainment of toring for the treatment of infections in acute burn patients
intravenous β-lactam regimens against Gram-negative [J]. Clin Ther，2017，39（8）：1649-1657.e3.
bacteria isolated in a Brazilian teaching hospital[J]. Rev [24] SWARTLING M，TÄNGDÉN T，LIPCSEY M，et al.
Soc Bras Med Trop，2015，48（5）：539-545. Therapeutic drug monitoring of vancomycin and merope‐
[11] LEE J M，LEE J W，JEONG T S，et al. Single-center phar‐ nem：illustration of the impact of inaccurate information
macokinetic study and simulation of a low meropenem in dose administration time[J]. Int J Antimicrob Agents，
concentration in brain-dead organ donors[J]. Antimicrob 2024，63（1）：107032.
Agents Chemother，2018，62（10）：e00542-18. [25] KÜHN D，METZ C，SEILER F，et al. Antibiotic therapeu‐
[12] BRADLEY J S，HARVEY H，STOUT D，et al. Subthera‐ tic drug monitoring in intensive care patients treated with
peutic meropenem antibiotic exposure in children with different modalities of extracorporeal membrane oxygena-
septic shock assessed by noncompartmental pharmacoki‐ tion（ECMO）and renal replacement therapy：a prospec‐
netic analysis in a prospective dataset[J]. Pediatr Crit Care tive，observational single-center study[J]. Crit Care，2020，
Med，2025，26（4）：e507-e515. 24（1）：664.
[13] World Health Organization. WHO handbook for guideline [26] SCHATZ L M，BRINKMANN A，RÖHR A，et al. Syste-
development：2nd ed[EB/OL]. [2024-05-30]. https：//www. matic evaluation of pharmacokinetic models for model-
who.int/publications/i/item/9789241548960. informed precision dosing of meropenem in critically ill
[14] PEREL P. The GRADE methodology for guideline deve- patients undergoing continuous renal replacement therapy
lopment[J]. Rheumatology（Oxford），2014，53（Suppl.2）： [J]. Antimicrob Agents Chemother，2023，67 （5） ：
i9-i10. e0010423.
[15] CHEN Y L，YANG K H，MARUŠIC A，et al. A reporting [27] TOMASELLI F，MAIER A，MATZI V，et al. Penetration
tool for practice guidelines in health care：the RIGHT of meropenem into pneumonic human lung tissue as mea‐
statement[J]. Ann Intern Med，2017，166（2）：128-132. sured by in vivo microdialysis[J]. Antimicrob Agents Che‐
[16] ZENG L N，YI Q S，HUANG L，et al. The guideline for mother，2004，48（6）：2228-2232.
therapeutic drug monitoring guidelines development[J]. J [28] MOUTON J W，VAN DEN ANKER J N. Meropenem
Evid Based Med，2022，15（3）：272-283. clinical pharmacokinetics[J]. Clin Pharmacokinet，1995，
[17] GUYATT G H，OXMAN A D，KUNZ R，et al. Going 28（4）：275-286.
from evidence to recommendations[J]. BMJ，2008，336 [29] SELIG D J，AKERS K S，CHUNG K K，et al. Merope‐
（7652）：1049-1051. nem pharmacokinetics in critically ill patients with or
[18] CUNHA B A. Meropenem in elderly and renally impaired without burn treated with or without continuous veno-
patients[J]. Int J Antimicrob Agents，1998，10（2）： venous haemofiltration[J]. Br J Clin Pharmacol，2022，88
107-117. （5）：2156-2168.
[19] LUQUE S，BENÍTEZ-CANO A，LARRAÑAGA L，et al. [30] BOONPENG A，JARURATANASIRIKUL S，JULLANGKOON
Pharmacokinetics and pharmacodynamics of meropenem M，et al. Population pharmacokinetics/pharmacodynamics
by extended or continuous infusion in low body weight and clinical outcomes of meropenem in critically ill patients
critically ill patients[J]. Antibiotics（Basel），2021，10 [J]. Antimicrob Agents Chemother，2022，66（11）：e00845-22.
（6）：666. [31] ANGELINI J，GIULIANO S，FLAMMINI S，et al. Me‐
[20] PEA F，COJUTTI P，SBROJAVACCA R，et al. TDM- ropenem PK/PD variability and renal function：“we go to‐
guided therapy with daptomycin and meropenem in a mor‐ gether”[J]. Pharmaceutics，2023，15（9）：2238.
bidly obese，critically ill patient[J]. Ann Pharmacother， [32] MAIMONGKOL P，YONWISES W，ANUGULRUENGKITT
2011，45（7/8）：e37. S，et al. Therapeutic drug monitoring of meropenem and
[21] ARESKOG LEJBMAN I，TORISSON G，RESMAN F，et pharmacokinetic-pharmacodynamic target assessment in
al. Beta-lactam antibiotic concentrations in critically ill pa‐ critically ill pediatric patients from a prospective observa‐
tients with standard and adjusted dosages：a prospective tional study[J]. Int J Infect Dis，2022，120：96-102.
observational study[J]. Acta Anaesthesiol Scand，2024，68 [33] YOU X，DAI Q，HU J，et al. Therapeutic drug monitoring

· 1964 · China Pharmacy 2025 Vol. 36 No. 16 中国药房 2025年第36卷第16期